Initial monotherapy and combination therapy and hypertension control the first year

Hypertension

Volumn 59, Issue 6, 2012, Pages 1124-1131

  Egan, Brent M ^a   Bandyopadhyay, Dipankar ^b   Shaftman, Stephanie R ^a   Wagner, C Shaun ^a   Zhao, Yumin ^a   Yu Isenberg, Kristina S ^c,d  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c NOVARTIS PHARMA AG   (Switzerland)

^d GLAXOSMITHKLINE   (United States)

Author keywords

Antihypertensive treatment; Blood pressure; Hypertension; Monotherapy; Single pill combination

Indexed keywords

ANTIHYPERTENSIVE AGENT;

ADULT; AGE; ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE MONITORING; BLOOD PRESSURE REGULATION; BODY MASS; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; DIABETES MELLITUS; ELECTRONIC MEDICAL RECORD; FEMALE; FOLLOW UP; FREE COMBINATION THERAPY; GENDER; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PHARMACEUTICAL CARE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SINGLE PILL COMBINATION THERAPY;

AFRICAN AMERICANS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; DRUG THERAPY; DRUG THERAPY, COMBINATION; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; OUTCOME ASSESSMENT (HEALTH CARE); PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; TIME FACTORS;

EID: 84861513966     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.112.194167     Document Type: Article

References (27)

1. Egan BM, Zhao Y, Axon RN. US trends in prevalence, awareness, treatment, and control of hypertension, 1988-2008. JAMA. 2010;303: 2043-2050.
2. US Census Bureau. Age and sex composition: 2010. http://www.census. gov/prod/cen2010/briefs/c2010br-03.pdf Accessed June 23, 2011.
3. Egan BM, Laken MA. Is blood pressure control to140/90 mmHg in 50% of all hypertensive patients as good as we can do in the United States? Or is this as good as it gets? Curr Opin Cardiol. 2011;26: 356-361.
4. Egan BM, Zhao Y, Axon RN, Brzezinski WA, Ferdinand KD. Uncontrolled and apparent treatment resistant hypertension in the U.S. 1988-2008. Circulation. 2011;124:1046-1058.
5. Bakris GL, Weir MR, on behalf of the Study of Hypertension and the Efficacy of Lotrel in Diabetes (SHIELD) Investigators. Achieving goal blood pressure in patients with type 2 diabetes: conventional versus fixed-dose combination approaches. J Clin Hypertens. 2003;5:202-209.
6. Weir MR, Levy D. Crikelair N. Rocha R. Meng X. Glazer R. Time to achieve blood-pressure goal: influence of dose of valsartan monotherapy and valsartan and hydrochlorothiazide combination therapy. Am J Hpyertens. 2007; 20:807-815.
7. Brown MJ, McInnes GT, Papst CC, Zhang J, MacDonald TM. Aliskiren and the Calcium Channel Blocker Amlodipine Combination as an Initial Treatment Strategy for Hypertension Control (ACCELERATE): a randomized, parallel-group trial. Lancet. 2011;377:312-320.
8. Bangalore S, Kamalakkannan G, Parker S, Messerli FH. Fixed-dose combinations improve medication compliance: a meta-analysis. Am J Med. 2007;120:713-719.
9. Julius S, Kjeldsen SE, Weber M, Brunner HR, Ekman S, Hansson L, Hua T, Laragh J, McInnes GT, Mitchell L, Plat F, Schork A, Smith B, Zanchetti A, for the VALUE Trial group. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet. 2004;363: 2022-2031.
10. Weber MA, Julius S, Kjeldsen SE, Brunner HR, Ekman S, Hansson L, Hua T, Laragh JH, McInnes GT, Mitchell L, Plat F, Schork MA, Smith B, Zanchetti A. Blood pressure dependent and independent effects of antihypertensive treatment in the VALUE Trial. Lancet. 2004;363: 2049-2051.
11. Kessler R, Glasgow RE. A proposal to speed translation of healthcare research into practice: dramatic change is needed. Am J Prev Med. 2011;40:637-644.
12. Tunis SR, Stryer DB, Clancy CM. Practical clinical trials: increasing the value of clinical research for decision making in clinical and health policy. JAMA. 2003;290:1624-1632.
13. Rehman SU, Hutchison FN, Hendrix K, Okonofua EC, Egan BM. Comparison of ethnic differences in blood pressure control at VA and non-VA sites. Arch Int Med. 2005;165:1041-1047.
14. Egan BM, Laken MA, Wagner CS, Mack SS, Seymour-Edwards K, Dodson J, Zhao Y, Lackland DT. Impacting population cardiovascular health through a community-based practice network: update on an ASHsupported collaborative. J Clin Hypertens. 2011;13:543-550.
15. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, Jones DW, Materson BJ, Oparil S, Wright JT Jr, Roccella EJ. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003;42: 1206-1252.
16. Okonofua EC, Simpson K, Jesri A, Rehman S, Durkalski V, Egan BM. Therapeutic inertia is an impediment to achieving the Healthy People 2010 blood pressure control goals. Hypertension. 2006;47:1-7.
17. Heckbert SR, Rutter CM, Oliver M, Williams LH, Ciechanowski P, Lin EHB, Katon WJ, Von Korff M. Depression in relation to long-term control of glycemia, blood pressure, and lipids in patients with diabetes. J Gen Intern Med. 2010;25:524-529.
18. Salanitro AH, Roumie CL. Blood pressure management in patients with diabetes. Clin Diab. 2010;28:107-114.
19. Feldman RD, Zou GY, Vandervoort MK, Wong CJ, Nelson SAE, Feagan BG. A simplified approach to the treatment of uncomplicated hypertension: a cluster randomized, controlled trial. Hypertension. 2009;53: 646-653.
20. Basile J, Neutel J. Overcoming clinical inertia to achieve blood pressure goals: the role of fixed-dose combination therapy. Ther Adv Cardiov Dis. 2010;4:119-127.
21. Flack JM, Sica DA, Bakris G, Brown AL, Ferdinand KC, Grimm RH Jr, Hall WD, Jones WE, Kountz DS, Lea JP, Nasser S, Nesbitt SD, Saunders E, Scisney-Matlock M, Jamerson KA, on behalf of the International Society on Hypertension in Blacks. Management of high blood pressure in blacks: an update of the International Society on Hypertension in Blacks. Hypertension. 2010;56:780-800.
22. Bosworth HB, Dudley T, Olsen M, Voils CI, Powers B, Goldstein MK, Oddone EZ. Racial differences in blood pressure control: potential explanatory factors. Am J Med. 2006;119:70.e9-70.e15.
23. Gupta AK, Arshad S, Poulter NR. Compliance, safety, and effectiveness of fixed-dose combinations of antihypertensive agents: a meta-analysis. Hypertension. 2010;55:399-407.
24. Wagner MM, Hogan WR. The accuracy of medication data in an outpatient electronic medical record. J Am Med Inform Assoc. 1996;3: 234-244.
25. Orrico KB. Sources and types of discrepancies between electronic medical records and actual outpatient medication use. J Mang Care Pharm. 2008;14:616-631.
26. Nassaralla CL, Naessens JM, Hunt VL, Bhagra A, Chaudhry R, Hansen MA, Tulledge-Scheitel SM. Medication reconciliation in ambulatory care: attempts at improvement. Qual Saf Health Care. 2009;18:402-407.
27. Jamerson K, Weber MA, Bakris GL, Dahlöf B, Pitt B, Shi V, Hestger A, Gupte J, Gatlin M, Velazques EJ, for the ACCOMPLISH Trial investigators. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med. 2008;359:2417-2428.